WINDTREE THERAPEUTICS INC /DE/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that WINDTREE THERAPEUTICS INC /DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $198.0K | Apr 3, 2020 |
| FY2019 | Jun 30, 2019 | $158.0K | Apr 3, 2020 |
| FY2019 | Mar 31, 2019 | $40.0K | Apr 3, 2020 |
| FY2019 | Dec 31, 2018 | $304.0K | Apr 3, 2020 |
| FY2019 | Sep 30, 2018 | $229.0K | Apr 3, 2020 |
| FY2019 | Jun 30, 2018 | $1.05M | Apr 3, 2020 |
| FY2019 | Mar 31, 2018 | $204.0K | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | $102.0K | Apr 23, 2019 |
| FY2018 | Sep 30, 2017 | $17.0K | Apr 23, 2019 |
| FY2018 | Jun 30, 2017 | $1.15M | Apr 23, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $102.0K | Apr 17, 2018 |
| FY2017 | Sep 30, 2017 | $17.0K | Apr 17, 2018 |
| FY2017 | Jun 30, 2017 | $1.15M | Apr 17, 2018 |
| FY2017 | Mar 31, 2017 | $219.0K | Apr 17, 2018 |
| FY2017 | Dec 31, 2016 | $900.0K | Apr 17, 2018 |
| FY2017 | Sep 30, 2016 | $961.0K | Apr 17, 2018 |
| FY2017 | Jun 30, 2016 | $106.0K | Apr 17, 2018 |
| FY2017 | Mar 31, 2016 | $75.0K | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $655.0K | Mar 31, 2017 |
| FY2016 | Sep 30, 2015 | $66.0K | Mar 31, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($1.79M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($20.29M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($39.21M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($67.64M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($32.57M) | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | ($7.38M) | Apr 3, 2020 |
| FY2019 | Sep 30, 2019 | ($7.13M) | Apr 3, 2020 |
| FY2019 | Jun 30, 2019 | ($6.44M) | Apr 3, 2020 |
| FY2019 | Mar 31, 2019 | ($6.54M) | Apr 3, 2020 |
| FY2019 | Dec 31, 2018 | ($9.04M) | Apr 3, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($26.14M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($20.60M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($41.33M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($77.28M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($30.32M) | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | ($4.55M) | Apr 3, 2020 |
| FY2019 | Sep 30, 2019 | ($7.19M) | Apr 3, 2020 |
| FY2019 | Jun 30, 2019 | ($6.50M) | Apr 3, 2020 |
| FY2019 | Mar 31, 2019 | ($6.66M) | Apr 3, 2020 |
| FY2019 | Dec 31, 2018 | ($4.85M) | Apr 3, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $16.28M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $8.34M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $11.10M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $17.79M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $15.37M | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | $2.14M | Apr 3, 2020 |
| FY2019 | Sep 30, 2019 | $3.79M | Apr 3, 2020 |
| FY2019 | Jun 30, 2019 | $3.41M | Apr 3, 2020 |
| FY2019 | Mar 31, 2019 | $3.34M | Apr 3, 2020 |
| FY2019 | Dec 31, 2018 | $2.37M | Apr 3, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $8.74M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $9.20M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $10.79M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $14.47M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $14.94M | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | $2.41M | Apr 3, 2020 |
| FY2019 | Sep 30, 2019 | $3.40M | Apr 3, 2020 |
| FY2019 | Jun 30, 2019 | $3.24M | Apr 3, 2020 |
| FY2019 | Mar 31, 2019 | $3.36M | Apr 3, 2020 |
| FY2019 | Dec 31, 2018 | $2.79M | Apr 3, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($15.40M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($13.44M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($19.45M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($23.66M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($25.32M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($24.66M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($15.78M) | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | ($21.05M) | Apr 23, 2019 |
| FY2017 | Dec 31, 2016 | ($33.59M) | Apr 17, 2018 |
| FY2013 | Dec 31, 2013 | ($40.45M) | Mar 17, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $12.0K | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $15.0K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $13.0K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $279.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $291.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $191.0K | Mar 29, 2021 |
| FY2018 | Dec 31, 2017 | $24.0K | Apr 23, 2019 |
| FY2016 | Dec 31, 2016 | $281.0K | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | $458.0K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $780.0K | Mar 29, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $27.88M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $32.41M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $37.95M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $74.79M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $112.89M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $118.98M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $119.40M | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | $3.35M | Apr 23, 2019 |
| FY2017 | Dec 31, 2016 | $9.70M | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $44.38M | Mar 31, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $14.70M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $29.02M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $27.94M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $32.91M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $43.33M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $44.04M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $51.28M | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | $27.27M | Apr 23, 2019 |
| FY2017 | Dec 31, 2016 | $38.53M | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $36.11M | Mar 31, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $10.00M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $3.39M | Apr 15, 2025 |
| FY2024 | Dec 31, 2022 | $10.01M | Apr 15, 2025 |
| FY2023 | Dec 31, 2021 | $41.88M | Apr 16, 2024 |
| FY2022 | Dec 31, 2020 | $69.55M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $74.94M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $68.11M | Mar 29, 2021 |
| FY2019 | Dec 31, 2017 | ($23.92M) | Apr 3, 2020 |
| FY2018 | Dec 31, 2016 | ($28.83M) | Apr 23, 2019 |
| FY2017 | Dec 31, 2015 | $8.27M | Apr 17, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $0 | Apr 15, 2025 |
| FY2024 | Jun 30, 2023 | $0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $3.06M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $15.68M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $15.68M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $15.68M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $15.68M | Apr 3, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($846.61M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($844.82M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($824.53M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($785.32M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($717.69M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($685.12M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($657.65M) | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | ($637.11M) | Apr 23, 2019 |
| FY2017 | Dec 31, 2016 | ($618.67M) | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | ($579.18M) | Mar 31, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.78M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $4.32M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $6.17M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $22.35M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $16.93M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $22.58M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $11.19M | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | $1.82M | Apr 23, 2019 |
| FY2017 | Dec 31, 2016 | $5.59M | Apr 17, 2018 |
| FY2016 | Nov 30, 2016 | $38.72M | Mar 31, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $20.30M | Mar 16, 2015 |
| FY2014 | Dec 31, 2013 | $18.35M | Mar 16, 2015 |
| FY2012 | Dec 31, 2012 | $217.0K | Mar 15, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (104) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | (4,718) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (62) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | (136) | Mar 31, 2023 |
| FY2018 | Dec 31, 2018 | (3) | Apr 23, 2019 |
| FY2018 | Sep 30, 2018 | (1) | Apr 23, 2019 |
| FY2018 | Jun 30, 2018 | 0 | Apr 23, 2019 |
| FY2018 | Mar 31, 2018 | (1) | Apr 23, 2019 |
| FY2018 | Dec 31, 2017 | 1 | Apr 23, 2019 |
| FY2018 | Sep 30, 2017 | (10) | Apr 23, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | (3) | Apr 23, 2019 |
| FY2018 | Sep 30, 2018 | (1) | Apr 23, 2019 |
| FY2018 | Jun 30, 2018 | 0 | Apr 23, 2019 |
| FY2018 | Mar 31, 2018 | (1) | Apr 23, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 23, 2019 |
| FY2018 | Sep 30, 2017 | (10) | Apr 23, 2019 |
| FY2018 | Jun 30, 2017 | (14) | Apr 23, 2019 |
| FY2018 | Mar 31, 2017 | (27) | Apr 23, 2019 |
| FY2016 | Dec 31, 2016 | 0 | Mar 31, 2017 |
| FY2016 | Sep 30, 2016 | (1) | Mar 31, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 256,397 | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | 6,664 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 772,202 | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 565,378 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 16.92M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 13.70M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 32.13M | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | 3.23M | Apr 23, 2019 |
| FY2017 | Dec 31, 2016 | 436,179 | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | 8.19M | Mar 31, 2017 |